Stephanie Serian
Family · Lynn Haven, FLNPI 1841299492
Payments from drug & device makers
Across 114 payments — averaging $25.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$586
- Novo Nordisk$438
- AstraZeneca$410
- AbbVie$304
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$163
- Pfizer$143
- plus $841 from 14 others
What the payments were for
- Food & beverage$2,884100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 24 | $586 |
| Novo Nordisk | 32 | $438 |
| AstraZeneca | 7 | $410 |
| AbbVie | 16 | $304 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $163 |
| Pfizer | 7 | $143 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $141 |
| Janssen Scientific Affairs, LLC | 2 | $136 |
| GSK | 1 | $117 |
| Medtronic | 4 | $113 |
| Amgen(2 entities) | 2 | $89 |
| Boehringer Ingelheim | 3 | $65 |
| Shockwave Medical, Inc | 1 | $54 |
| Supernus Pharmaceuticals, Inc. | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Exact Sciences | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Lundbeck LLC | 1 | $11 |
| Genentech USA, Inc. | 2 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,884 in reported general payments places this provider in the 85th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 30 | $32,448 |
| JardianceEmpagliflozin | 11 | $12,689 |
| XareltoRivaroxaban | 18 | $10,205 |
| Rosuvastatin Calcium | 62 | $1,009 |
| Nebivolol Hcl | 14 | $792 |
| Lisinopril | 85 | $709 |
| Metoprolol Succinate | 28 | $659 |
| Pravastatin Sodium | 32 | $617 |
| Levothyroxine Sodium | 61 | $605 |
| Buspirone Hcl | 52 | $544 |
| Amlodipine Besylate | 78 | $542 |
| FenofibrateFenofibrate,micronized | 12 | $468 |
| Atorvastatin Calcium | 48 | $457 |
| Losartan Potassium | 39 | $446 |
| Gabapentin | 19 | $446 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $143 | $32,44830 claims |
| Boehringer IngelheimJardiance | $65 | $12,68911 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $16 | $26722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 14,618 family providers in Florida.
Other family in Lynn Haven
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.